Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia

Journal of Clinical Oncology

Volumn 19, Issue 6, 2001, Pages 1589-1599

  Dorr, R ^a   Karanes, C ^a   Spier, C ^a   Grogan, T ^a   Greer, J ^a   Moore, J ^a   Weinberger, B ^a   Schiller, G ^a   Pearce, T ^a   Litchman, M ^a   Dalton, W ^a   Roe, D ^a   List, A F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION;

EID: 0035868894     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.6.1589     Document Type: Article

References (58)

1. Acute leukemias
2. Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine or daunorubucin in acute myelocytic leukemia
3. Treatment of acute leukemia in adults
4. Intensive chemotherapy for acute myeloid leukemia
5. Treatment of acute non-lymphocytic leukemia: Use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens
6. DAT (daunorubucin, cytarabine, 6-thioguanine) in acute myeloid leukemia
7. Cytosine arabinoside (NSC-63868) and daunorubucin (NSC-83142) therapy in acute nonlymphocytic leukemia
8. Maintenance of remission in adult acute non-lymphoblastic leukemia using intermittent courses of cytosine arabinoside 9NSC-63878) and 6-thioguanine (NSC-752)
9. The treatment of acute myeloid leukemia in adults
10. MDRI gene expression and treatment outcome in acute myeloid leukemia
11. Clinical significance of multidrug resistance P-glycoprotein expression in acute nonlymphoblastic leukemia cells at diagnosis
12. Overexpression of the mdr 1 gene in blast cells from patients with acute myelogenous leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A
13. Clinical trials of modulation of multidrug resistance
14. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype
15. Multidrug resistance and its pharmacologic modulation in acute leukemia
16. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A
17. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance
18. Phase 1 trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
19. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
20. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubucin-resistant Ehrlich ascites tumor
21. Reversal of typical immunosuppressive analogs SDZ PSC-833 in Chinese hamster ovary cells expressing the mdr-1 phenotype
22. In vitro circumvention of p-glycoprotein-mediated resistance of tumor cells with SDZ-PSC 833
23. Phase 1 study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukemia
24. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype
25. Optimization of immunohistochemical p-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies in patients with multiple myeloma
26. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
27. Detection of multidrug resistance gene expression in multiple myeloma
28. Quantitative polymerase chain reaction analysis of mdr-1 mRNA in multiple myeloma cell lines and clinical specimens
29. Multivariate analysis of prognostic factors in acute myeloid leukemia: Value of clonogenic leukemic cell properties
30. A method for the simultaneous measurement of the new anthracycline derivative 4′deoxydoxorubicin and its metabolites by reverse phase liquid chromatography
31. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
32. Treatment failure in AML
33. Nonparametric estimation from incomplete observations
34. Evaluation of survival data and two new rank order statistics arising in its consideration
35. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
36. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
37. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
38. Dose-finding study of PSC833 (Valspodar) with daunorubicin and cytarabie to reverse multidrug resistance in elderly patients with untreated acute myeloid leukemia
39. Parallel phase 1 studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420
40. A phase 1 study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group study (9617)
41. Characterization of a new drug-resistant human myeloma cell line that expresses Pglycoprotein
42. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines
43. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines
44. Drug resistance-reversal strategies: Comparison of experimental data with model predictions
45. Increased chemosensitivity to doxorubicin of intrinsically multidrug resistant human colon carcinoma cells by prolonged exposure to verapamil
46. Daunomycin administered by continuous infusion is effective in the treatment of acute nonlymphocytic leukemia
47. Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia
48. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
49. Clinical evaluation of long-term continuous-infusion doxorubicin
50. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia
51. Benefit of cyclosporine (CSA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study
52. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver
53. Comparative studies on the in vitro killing of human normal and leukemic clonogenic cell (CFUC) by daunorubucin, daunorubicinol and daunorubicin-DNA complex
54. Comparative uptake, metabolism and retention of anthracyclines by tumors growing in vitro
55. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture
56. Essai de chimiothérapie anticancéreuse par la duborimycine: Analyse de 151 observations
57. A multidrug resistance transporter from human MCF- 7 breast cancer cells
58. Expression of the human major vault protein LRP in acute myeloid leukemia